DRIO

DarioHealth Corp. (DRIO) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. DarioHealth Corp. is a global digital therapeutics (DTx) company providing personalized, evidence-based interventions for chronic conditions (diabetes, hypertension, weight management) and behavioral health. The company operates as a single reporting segment with a vertically integrated model combining FDA-cleared hardware, AI-driven analytics, and coaching. As of August 11, 2026, there were 9,799,481 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 3.6% QoQ and 11.2% YoY. The decline was primarily driven by a reduction in revenue from the pharmaceutical channel due to non-recurring revenue recognized in the prior year, partially offset by growth in channel partner and direct-to-consumer sales.
• Improved Margins: Gross margin improved to 61.7% in Q2 2026 from 55.2% in Q2 2025. This was driven by lower amortization of acquired technology, reduced hosting costs, and a $369 benefit from IEEPA tariff refunds recorded in cost of revenues.
• Expense Reduction: Operating expenses decreased significantly. R&D expenses dropped 43.6% YoY due to post-merger integration efficiencies and AI utilization. Sales and marketing expenses fell 5% YoY, and G&A expenses fell 19.1% YoY, largely due to reduced stock-based compensation and professional fees.
• Net Loss Improvement: Net loss decreased 39% YoY for the quarter and 27.2% YoY for the six-month period, reflecting the combined impact of improved gross profit and reduced operating expenses.

Guidance, Outlook, and Risks

• Liquidity & Capital: Management believes current cash, short-term deposits, and proceeds from a subsequent registered direct offering (closed July 23, 2026, raising ~$23.5M gross) are sufficient to fund operations for at least 12 months. The company maintains a $32.5M credit facility with Callodine (maturity April 2030) with an outstanding balance of $31.1M.
• Tariff Uncertainty: While the company recorded a receivable for ~$536 in IEEPA tariff refunds following a Supreme Court ruling, the timing and full realization of these refunds remain subject to administrative processes. Additionally, new tariff policies announced by the U.S. administration create uncertainty regarding future import costs.
• Geopolitical Risks: The company highlights risks related to unrest and armed conflict in Israel and the Middle East, which could impact operations given its significant R&D presence in Israel.
• Debt Covenants: The company is currently in compliance with its credit agreement covenants, which include a minimum consolidated unencumbered liquid assets covenant of $10,000.

Investor Verification Checklist

• Tariff Refund Realization: Verify the actual cash receipt of the ~$536 IEEPA tariff refund and the impact of any new U.S. tariff policies on hardware costs.
• Pharma Channel Stability: Assess the sustainability of revenue streams following the loss of non-recurring pharma revenue in the prior year.
• Debt Service Capacity: Monitor the company's ability to meet the $10M liquid assets covenant and service the $31M+ debt obligation, particularly given the interest rate of SOFR + 7.75%.
• Post-Merger Integration: Evaluate whether the reported cost efficiencies from the Twill acquisition are sustainable or if they mask underlying operational challenges.
• Subsequent Financing: Confirm the dilution impact and use of proceeds from the July 2026 registered direct offering.